As diabetes care continues to be a major focus, new treatments are emerging . Retatrutide, Tirzepatide, and Semaglutide represent a noteworthy advancement in GLP-1 receptor agonist medications. While all seek https://siambookmark.com/story22178553/the-new-drug-vs-tirzepatid-vs-semaglutide-a-head-to-head-analysis